ROSEN, LEADING TRIAL ATTORNEYS, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Spectrum Pharmaceuticals, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on September 24, 2025 [1]. Group 1: Class Action Details - Investors who bought Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed against Spectrum Pharmaceuticals due to alleged false or misleading statements regarding its PINNACLE Study, which involved the drug poziotinib for lung cancer treatment [5]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4].